## Contents

*Preface* ................................................................................................................ v
*Contributors* ......................................................................................................... ix

1. Targeting Cancer with Small-Molecular-Weight Kinase Inhibitors .................. 1
   Doriano Fabbro, Sandra W. Cowan-Jacob, Henrik Möbitz, and Georg Martiny-Baron

2. Small-Molecule Protein and Lipid Kinase Inhibitors in Inflammation and Specific Models for Their Evaluation ................................ 35
   Matthias Gaestel and Alexey Kotlyarov

3. Measuring the Activity of Leucine-Rich Repeat Kinase 2: A Kinase Involved in Parkinson's Disease ........................................... 45
   Byoung Dae Lee, Xiaojie Li, Ted M. Dawson, and Valina L. Dawson

4. Measuring PI3K Lipid Kinase Activity .......................................................... 55
   Elisa Ciraolo, Alessia Perino, and Emilio Hirsch

5. A Fluorescence Polarization Assay for the Discovery of Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1 .......................... 69
   Wolfgang Reindl, Klaus Strebhardt, and Thorsten Berg

6. Assessment of Hepatotoxicity Potential of Drug Candidate Molecules Including Kinase Inhibitors by Hepatocyte Imaging Assay Technology and Bile Flux Imaging Assay Technology ........................ 83
   Jinghai J. Xu, Margaret C. Dunn, Arthur R. Smith, and Eric S. Tien

   Oleg Fedorov, Frank H. Niesen, and Stefan Knapp

8. Chemoproteomic Characterization of Protein Kinase Inhibitors Using Immobilized ATP ................................................................. 119
   James S. Duncan, Timothy A. J. Haystead, and David W. Litchfield

   Jenny J. Fischer, Olivia Y. Graebner (née Baessler), and Mathias Dreger

10. Affinity Purification of Proteins Binding to Kinase Inhibitors Immobilized on Self-Assembling Monolayers ....................................... 149
    Marcus Bantscheff, Scott Hobson, and Bernhard Kuster

11. Kinase Inhibitor Profiling Using Chemoproteomics ...................................... 161
    Markus Schirle, Eugene C. Petrella, Scott M. Brittain, David Schwalb, Edmund Harrington, Ivan Cornella-Taracido, and John A. Tallarico

12. Covalent Cross-Linking of Kinases with Their Corresponding Peptide Substrates ................................................................. 179
    Alexander V. Statsuk and Kevan M. Shokat
13 Receptor Tyrosine Kinase Inhibitor Profiling Using Bead-Based Multiplex Sandwich Immunoassays .......................................................... 191

Oliver Pötz, Nicole Schneiderhan-Marra, Tanja Henzler, Thomas Herget, and Thomas O. Joos

14 Monitoring Phosphoproteomic Response to Targeted Kinase Inhibitors Using Reverse-Phase Protein Microarrays ................................ 203

Gabriela Lavezzari and Mark R. Lackner

15 Measuring Phosphorylation-Specific Changes in Response to Kinase Inhibitors in Mammalian Cells Using Quantitative Proteomics ................. 217

Nurhan Özlü, Marc Kirchner, and Judith Jebanathirajah Steen

16 Investigation of Acquired Resistance to EGFR-Targeted Therapies in Lung Cancer Using cDNA Microarrays ............................................. 233

Kian Kani, Rafaella Sordella, and Parag Mallick

Index ............................................................................................................. 255
Kinase Inhibitors
Methods and Protocols
Kuster, B. (Ed.)
2012, XI, 256 p., Hardcover
A product of Humana Press